SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report)’s share price shot up 143.4% during mid-day trading on Tuesday . The company traded as high as C$11.32 and last traded at C$11.32. 993 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 2,350 shares. The stock had previously closed at C$4.65.
SanBio Stock Performance
The stock’s 50-day moving average price is C$6.40 and its 200-day moving average price is C$5.07.
SanBio Company Profile
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
See Also
- Five stocks we like better than SanBio
- How Technical Indicators Can Help You Find Oversold Stocks
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- What Are the U.K. Market Holidays? How to Invest and Trade
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
